Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the first quarter, after the closing bell on Monday, May 5.

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.29 per share, down from $4.76 per share in the year-ago period. Vertex Pharmaceuticals projects to report quarterly revenue at $2.86 billion, compared to $2.69 billion a year earlier, according to data from Benzinga Pro.

On March 28, Vertex Pharmaceuticals announced updates about its type 1 diabetes (T1D) portfolio. The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, including of explanted devices.

Vertex Pharmaceuticals shares gained 0.5% to close at $501.15 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

• Cantor Fitzgerald analyst Carter Gould assumed an Overweight rating with a price target of $535 on April 22, 2025. This analyst has an accuracy rate of 60%.
• B of A Securities analyst Ying Huang maintained a Buy rating and raised the price target from $555 to $567 on March 31, 2025. This analyst has an accuracy rate of 65%.
• Truist Securities analyst Joon Lee maintained a Buy rating and increased the price target from $460 to $520 on Feb. 11, 2025. This analyst has an accuracy rate of 77%.
• Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and raised the price target from $450 to $459 on Feb. 11, 2025. This analyst has an accuracy rate of 61%.
• Wells Fargo analyst Mohit Bansal downgraded the stock from Overweight to Equal-Weight with a price target of $460 on Jan. 30, 2025. This analyst has an accuracy rate of 72%.

Considering buying VRTX stock? Here’s what analysts think: